Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity - Newsome, Philip; Francque, Sven; Harrison, Stephen; Ratziu, Vlad; Van Gaal, Luc; Calanna, Salvatore; Hansen, Morten; Linder, Martin; Sanyal, Arun (Alimentary pharmacology & therapeutics, 2019)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine transaminase; Alanine Transaminase - metabolism; Biomarkers - metabolism; Body weight; Body Weight - drug effects; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Clinical trials; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Double-Blind Method; Fatty liver; Female; Glucagon; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptides - pharmacology; Glucagon-Like Peptides - therapeutic use; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity; Inflammation - complications; Inflammation - drug therapy; Inflammation - metabolism; Liver - drug effects; Liver - enzymology; Liver - metabolism; Liver diseases; Male; Middle Aged; Multicenter Studies as Topic - statistics & numerical data; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity; Obesity - complications; Obesity - drug therapy; Obesity - metabolism; Original; Peptides; Randomized Controlled Trials as Topic - statistics & numerical data; Retrospective Studies; Statistical analysis; Weight control; Weight Reduction Programs; Young Adult